Methods for capturing a target nucleic acid from a sample by using a capture probe that binds nonspecifically to the target nucleic acid and binds specifically to an immobilized probe via a specific binding pair that has one member on the capture probe and one member on the immobilized probe are disclosed. Compositions that include a capture probe that binds nonspecifically to a target nucleic acid and specifically to an immobilized probe via binding of members of a specific binding pair in a solution phase of a reaction mixture are disclosed.

Provided are an expression inhibitor of an inflammation promoting factor based on the discovery of a new factor influencing the expression amount/level of an inflammation promoting factor, and a development tool therefor. Provided are also a diagnostic agent and a diagnosis method for immune diseases, inflammatory diseases, painful conditions and similar. More specifically provided are: an expression inhibitor of an inflammation promoting factor containing at least one kind of inhibitor selected from the group consisting of RBMS2 expression inhibitor and RBMS2 function inhibitor; a screening method using as an indicator the expression or the function of RBMS2; an expression cassette useful for said method; as well as a diagnostic agent containing a product detection agent for RBMS2 gene expression and disease detection method using as an indicator RBMS2 gene expression amount/level.

A complex of mRNA encoding a target gene with RNA oligomers, wherein the RNA oligomers are at least two kinds of RNA oligomers comprising RNA sequences of (a) or (b), the at least two kinds of RNA oligomers are hybridizable respectively with sequences, said sequences being different from each other, in the mRNA sequence, and the complex is formed when a first sequence of the RNA oligomers hybridizes with different mRNA from the second sequence of the RNA oligomers: (a) an RNA sequence which comprises a first sequence consisting of 12-40 bases and being complementary to the mRNA sequence, a linker sequence consisting of 0-100 bases and a sequence which is the same as the first sequence, in this order; and (b) an RNA sequence which comprises a first sequence, which has a 90% or more identity with a sequence consisting of 12-40 bases and being complementary to the mRNA sequence and is hybridizable with mRNA, a linker sequence consisting of 0-100 bases and a second sequence which is the same as the first sequence, in this order. Thus, a novel method for mRNA stabilization is provided.

The present invention relates to A multicomponent system wherein a first component is an engineered antigen-presenting cell (eAPC) designated component A and a second component is a genetic donor vector, designated component C, for delivery of one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and/or an analyte antigenic molecule (aAM), wherein component A a. Lacks endogenous surface expression of at least one family of aAPX and/or aAM and b. Contains at least two genomic receiver sites, designated component B and component D, each for integration of at least one ORF encoding at least one aAPX and/or aAM, and component C is matched to a component B, and wherein component C is designed to deliver c. A single ORF encoding at least one aAPX and/or aAM or d. Two or more ORF encoding at least one aAPX and/or aAM,
wherein the genomic receiver sites B and D are synthetic constructs designed for recombinase mediated exchange (RMCE).

Disclosed are components and methods for producing toxic RNAs and/or extracellular vesicles comprising the toxic RNAs in cells that are resistant to the toxic RNAs, which toxic RNAs may include toxic shRNA/siRNA and/or toxic pre-miRNA/miRNA. The disclosed components may include engineered cells that can be utilized to express the toxic RNAs, in which the engineered cells do not express one or more genes that are required for processing the toxic RNAs for RNA interference (RNAi) and/or one or more genes that are required for executing RNAi. The toxic RNAs and/or extracellular vesicles comprising the toxic RNAs may be utilized in methods for treating diseases and disorders through RNAi.

Disclosed are nucleic acid oligomer compounds and to their use in compositions and methods for inhibiting proliferation, survival or viability of cancer cells including prostate, lung, pancreatic, breast, cervical and bone cancer cells.

Disclosed are methods and compositions for inhibiting DNA synthesis in a cell using RNA. Inhibition of DNA synthesis by RNA can be used, for example, in analytical methods, as a research tool to affect cells under study, to synchronize cell cycle in a cell culture, and to inhibit cell growth. For example, inhibition of DNA synthesis in cancer cells can be used to inhibit cancer cells and treat cancer. The RNA can be any RNA, such as whole cell RNA, whole cell mRNA, whole cell ribosomal RNA, whole cell transfer RNA, synthetic RNA, recombinant RNA, modified RNA, or a combination. The composition can comprise RNA and a pharmaceutically acceptable carrier or RNA, a targeting molecule, and a pharmaceutically acceptable carrier. The targeting molecule can be a tumor-targeting peptide.

The present invention relates to tetramolecular parallel G-quadruplex-forming oligonucleotides. If G-quadruplexes are of prime importance in biology, their use is hampered by the propensity of G4-prone DNA molecules, in particular G4-prone DNA molecules of long size, to adopt many different G4 topological conformations or other alternative foldings. By introducing a lipid modification at the end of the oligonucleotide, the inventors succeeded in obtaining long tetramolecular parallel G-quadruplexes (tpG4). The present invention thus concerns an oligonucleotide modified by substitution at the 5 or the 3 end by a lipid moiety, wherein said oligonucleotide comprises a nucleic acid sequence of at least 10 nucleotides, said nucleic acid sequence including a series of at least 4 consecutive guanine residues located in the middle of said sequence. A tetramolecular parallel G-quadruplex comprising 4 identical modified oligonucleotides as defined above, wherein each of the 4 consecutive guanine residues included in the middle of the nucleic acid sequence of each oligonucleotide respectively form G-quartets with the corresponding guanine residues of the other 3 oligonucleotides, said G-quartets being stabilized by - staking and Hoogsteen hydrogen bonding, is also contemplated. The modified oligonucleotides have preferably the general formula (I) or (II), wherein the oligonucleotides are modified by substitution at the 5 or the 3 end by a lipid moiety, and said oligonucleotides comprise a nucleic acid sequence of at least 10 nucleotides, said nucleic acid sequence including a series of at least 4 consecutive guanine residues located in the middle of said sequence.

##STR00001##

This invention discloses a nucleic acid aptamer AS1411 modified DNA tetrahedron. The preparation method includes the steps of (1) binding an AS1411 sequence to the 5 terminal of any DNA single-strand in a DNA tetrahedron, synthesizing the DNA, dissolving obtained DNA powder with ddH.sub.2O; (2) measuring an absorbance of the DNA and then calculating a total volume of the four single strands; (3) pipetting the DNA obtained in step (1) according to the calculation results in step (2), mixing the DNA with a TM buffer, mixing the mixture uniformly with vortex vibration, and performing a PCR progress. The preparation method is simple. The produced product can effectively solve the problem that the unmodified DNA tetrahedron cannot enter the nucleus and the problem that the AS1411 cannot carry drugs directly.

The present disclosure provides donor polynucleotides, genome editing systems, methods, and kits which correct or induce a mutation in a gDNA.